Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide for diastolic cardiac function and myocardial perfusion in type 2 diabetes
2015-000410-22Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Jun 2015
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), diastolic dysfunction and heart failure with preserved ejection fraction (HFpEF) comparing Liraglutide with Placebo (2 arms). Primary endpoint: Change in diastolic properties assessed by cardiac MRI. Started Jun 2015; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)diastolic dysfunctionheart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on 2015-000410-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000410-22.